Single-agent Aredia for relapsed/refractory multiple myeloma.

被引：0
|
作者：
Berenson, JR
Webb, IJ
Anderson, K
Schlossman, R
Vescio, R
Doss, D
Goon, B
Swift, R
VonTeichert, J
Kowalski, M
Seaman, J
机构：
[1] W LA VA Med Ctr, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Novartis Pharmaceut Corp, Clin Res, E Hanover, NJ USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4601
引用
收藏
页码：307B / 307B
页数：1
相关论文
共 50 条
  • [1] A phase II dose-ranging trial of single-agent pamidronate for relapsed/refractory multiple myeloma.
    Berenson, J
    Webb, I
    Henick, K
    Vescio, R
    Swift, R
    Anderson, K
    Seaman, J
    BLOOD, 1998, 92 (10) : 107A - 107A
  • [2] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (04) : 772 - 778
  • [3] Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
    Prince, H. Miles
    Adena, Michael
    Smith, Dell Kingsford
    Hertel, Judy
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 93 - 99
  • [4] Evaluation of gemcitabine in relapsed or refractory multiple myeloma.
    Leleu, X
    Troncy, J
    Micol, JB
    Bouafia, F
    Guieze, R
    Yakoub-Agha, I
    Depil, S
    Kuhnovski, F
    Terriou, L
    Michallet, M
    Facon, T
    Dumontet, C
    BLOOD, 2003, 102 (11) : 384B - 384B
  • [5] Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Hussein, M. A.
    Richardson, P. G.
    Jagannath, S.
    Singhal, S.
    Bensinger, W.
    Knight, R.
    Zeldis, J. B.
    Yu, Z.
    Olesnyckyj, M.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
  • [7] Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review
    Harrison, SJ
    Prince, M
    Adena, M
    Smith, DK
    Hertel, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 104 - 105
  • [8] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [9] Oral idarubicin as single agent therapy for patients with relapsed multiple myeloma.
    Sumpter, K
    Powles, R
    Raje, N
    Kulkarni, S
    Ramiah, V
    Hill, M
    Horton, C
    Milan, S
    Mehta, J
    Singhal, S
    Rodriguez, M
    Mateos, P
    Laufente, A
    Treleaven, J
    BLOOD, 1997, 90 (10) : 4144 - 4144
  • [10] Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma
    Richardson, Paul G.
    Mitsiades, Constantine
    Ghobrial, Irene
    Anderson, Kenneth
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (06) : 598 - 608
12345